Janux Therapeutics (NASDAQ:JANX) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Janux Therapeutics (NASDAQ:JANX) posted its quarterly earnings data on Wednesday. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18), Briefing.com reports. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The company’s revenue was down 82.6% compared to the same quarter last year.

Janux Therapeutics Stock Up 1.8 %

Shares of JANX stock traded up $0.97 during trading hours on Friday, reaching $55.18. 264,000 shares of the stock traded hands, compared to its average volume of 711,018. The firm has a market capitalization of $2.88 billion, a PE ratio of -46.33 and a beta of 3.52. Janux Therapeutics has a 1-year low of $5.65 and a 1-year high of $65.60. The business has a fifty day moving average price of $48.88 and a 200 day moving average price of $46.35.

Wall Street Analysts Forecast Growth

JANX has been the topic of several research analyst reports. UBS Group started coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $100.00 price target on shares of Janux Therapeutics in a research report on Thursday. Wedbush restated an “outperform” rating and set a $74.00 price objective on shares of Janux Therapeutics in a research report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a report on Thursday. Finally, Scotiabank reduced their target price on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $66.44.

Insider Buying and Selling

In other news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00. Following the completion of the sale, the insider now owns 3,162,851 shares of the company’s stock, valued at $132,839,742. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the completion of the sale, the chief executive officer now directly owns 282,054 shares of the company’s stock, valued at $15,101,171.16. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $42.00, for a total value of $4,551,330.00. Following the sale, the insider now owns 3,162,851 shares of the company’s stock, valued at approximately $132,839,742. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 420,610 shares of company stock valued at $19,288,666. Company insiders own 29.40% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.